Epicurus, 30 mg capsules 14 pcs

Epicur is an anti-ulcer agent. Specific proton pump inhibitor (H+K+ATPase); metabolized in the parietal cells of the stomach to active sulfonamide derivatives, which inactivate sulfhydryl groups of H+K+ATPase. Blocks the final stage of hydrochloric acid synthesis, reducing basal and stimulated secretion, regardless of the nature of the irritant.

The inhibition of hydrochloric acid production at a dose of 30 mg is 80-97%. Does not affect the motility of the gastrointestinal tract. The inhibitory effect increases during the first four days of administration. After discontinuation of the dose, acidity remains below 50% of the basal level for 39 hours, “ricochet” increase in secretion is not observed. Secretory activity is restored 3-4 days after discontinuation of the drug. In patients with Zollinger-Ellison syndrome the action is longer.

Pharmacokinetics

Absorption – high, bioavailability – 80% (eating reduces absorption and bioavailability by 50%, but inhibitory effect on gastric secretion remains the same, regardless of meals).

The time of onset of maximum concentration (C max) after oral administration of 30 mg is 1.5-2.2 h, Cmax- 0.75-1.15 mg/l. Binding with plasma proteins is 97.7-99.4%. It is actively metabolized by the “primary passage” through the liver.

The elimination half-life is 1.3-1.7 hours. Excretion by the kidneys (as metabolites) – 14-23% and through the intestine. With hepatic insufficiency and in elderly patients excretion slows down.

Indications

Active ingredient

Composition

1 capsule contains:

Active substances:

pellets of lansoprazole – 353 mg, containing lansoprazole – 30 mg,

Auxiliary substances:

sugar pellets (sucrose),

sugar syrup (sucrose),

mannitol,

calcium carboxymethylcellulose (calcium carmellose),

magnesium carbonate,

sodium phosphate displaced (sodium hydrophosphate),

sodium lauryl sulfate,

polyvinylpyrrolidone K-30 (povidone),

tween 80 (polysorbate 80),

hydroxypropyl methylcellulose (hypromellose),

acrylic coating L30DA (methacrylic acid),

talc,

polyethylene glycol 6000 (macrogol),

titanium dioxide,

sodium hydroxide.

Solid gelatin capsules (quinoline yellow [E 104], patent blue V , gelatin) methyl parahydroxybenzoate, propyl parahydroxybenzoate)

How to take, the dosage

Ingestion. Capsules should be swallowed whole without chewing.

Penal ulcer in the phase of exacerbation – 30 mg per day for 2-4 weeks (in resistant cases up to 60 mg per day).

Gastric ulcer in acute phase and erosive-ulcerous esophagitis – 30-60 mg per day for 4-8 weeks.

Errotic ulcerative lesions of the gastrointestinal tract caused by taking nonsteroidal anti-inflammatory preparations – 30 mg daily for 4-8 weeks.

Eradication of Helicobacterpylori- 30 mg 2 times a day for 7 to 14 days in combination with antibacterial agents. Recommended duration of treatment in various regimens of combined anthelicobacter therapy is 7 days.

Antiretroviral treatment of gastric and 12 duodenal ulcers is 30 mg once daily.

Antiretroviral treatment of reflux esophagitis – 30 mg once daily for a long time (up to 6 months).

Zollinger-Ellison syndrome – dose is adjusted individually until basal secretion levels of less than 10 mmol/h are achieved.

Interaction

Delays elimination of drugs metabolized in the liver by microsomal oxidation (including diazepam, phenytoin, indirect anticoagulants). Reduces clearance of theophylline by 10%.

Alter the pH-dependent absorption of drugs belonging to the groups of weak acids (retardation) and bases (acceleration).

Sucralfate reduces the bioavailability of lansoprazole by 30% (the interval between the intake of these drugs should be 30-40 minutes)

Antacids slow down and decrease absorption of lansoprazole (they should be prescribed 1 hour or 1-2 hours after taking lansoprazole).

Special Instructions

Before starting treatment, it is necessary to rule out the presence of a malignant process in the upper gastrointestinal tract, as taking the drug can “mask” the symptoms and make diagnosis difficult.

Contraindications

With caution: Hepatic and/or renal insufficiency. Older age.

Side effects

The digestive system: increased or decreased appetite, nausea, abdominal pain, rarely – diarrhea or constipation; in some cases – ulcerative colitis, candidiasis of the gastrointestinal tract, increased activity of “liver” enzymes, increased blood bilirubin levels.

Nervous system disorders: headache; rarely – malaise, dizziness, somnolence, depression, anxiety.

Respiratory system disorders: rarely – cough, pharyngitis, rhinitis, upper respiratory tract infection, flu-like syndrome.

Hematopoietic organs: rare – thrombocytopenia (with hemorrhagic manifestations); anemia in rare cases.

Allergic reactions: skin rash; in some cases – photosensitization, erythema multiforme.

Others: rarely – myalgia, alopecia.

Pregnancy use

It is contraindicated in the first trimester. In II and III trimester it is possible if the expected benefit of therapy exceeds the potential risk to the fetus. Breastfeeding should be stopped during treatment.

Similarities